Figma Shares Indicated To Open $105/$110
Cencora, Inc. (NYSE:COR), a prominent healthcare services provider with a market capitalization of $49 billion, has reported that its Executive Chairman, Steven H. Collis, sold shares valued at approximately $3.66 million on February 27, 2025. The transactions involved the sale of 14,579 shares at a price of $251.08 each. The stock, which has gained 11% year-to-date according to InvestingPro data, is currently trading near its 52-week high. This sale was conducted as part of a prearranged trading plan under Rule 10b5-1, which allows insiders to set up a predetermined plan for selling stocks.
In addition to the sales, Collis exercised options to acquire 12,579 shares at a price of $86.09 per share, resulting in a transaction total of about $1.08 million. Following these transactions, Collis owns approximately 319,913 shares directly.
This activity comes as part of routine financial management by insiders, providing them with liquidity while maintaining compliance with securities regulations. For deeper insights into Cencora’s valuation and performance metrics, including 13 additional ProTips and comprehensive financial analysis, investors can access the full research report on InvestingPro.
In other recent news, Cencora, Inc. has announced an upward revision of its fiscal year 2025 adjusted earnings per share (EPS) guidance following the acquisition of Retina Consultants of America for $4.4 billion. The acquisition, which involves an 85% stake in the organization, has led Cencora to update its EPS forecast to a range of $15.15 to $15.45, up from the previous estimate of $14.80 to $15.10. Leerink Partners responded to Cencora’s strong first-quarter results by raising its price target to $301, maintaining an Outperform rating, citing the company’s robust pharmaceutical distribution segment. Meanwhile, Mizuho (NYSE:MFG) Securities initiated coverage with an Outperform rating and a $280 price target, expressing confidence in Cencora’s financial goals and strong position in the Specialty/Biopharma Services sector.
In another development, BofA Securities increased its price target for Cencora to $260, following the company’s virtual Product Showcase event, highlighting its innovation in supply chain technology solutions. Additionally, Cencora announced the upcoming retirement of two long-standing board members, Richard W. Gochnauer and Kathleen W. Hyle, at the next Annual Meeting of Stockholders in March 2025. The board will reduce from 13 to 11 members, with no successors announced yet. These recent developments reflect Cencora’s strategic initiatives and ongoing efforts to strengthen its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.